Gamida Cell is up 82% after Efficient and Safe Results in Phase 3 Study of Omidubicel

Gamida Cell has been on our watch list since last year. We started analyzing the genomic revolution when Gamida Cell caught our attention back then. This is a very crucial point, where breakthrough advanced technology and science come together to take technological advances one step ahead and cure diseases.

Summary

  • Gamida Cell closed yesterday on $9.89 and after the efficiency and safety results of the Phase 3 study were announced during the after-hours market it is now up 82% at a price of $18.03.
  • The study included 125 people with ages from 12-65 from all around the globe. People with high-risk hematologic malignancies undergoing a bone marrow transplant participated compared to a group of patients who received a standard umbilical cord blood transplant.
  • The results of the Phase 3 study of omidubicel showed that it resulted in faster hematologic results, fewer bacterial and viral infections and fewer days spent in the hospital.
  • Omidubicel is an investigational therapy, and its safety and efficacy have not been established by the FDA or any other health authority.

About Gamida Cell

Gamida cell (NASDAQ: GMDA) is an advanced cell therapy company engaged in the cure of blood cancer and serious hematologic diseases. The company’s headquarters are in Israel and it was founded in 1998. In October 2018, Gamida Cell went public and raised $50 million. 

The company has a unique approach that aims to improve and change the treatment of deadly diseases beyond what is possible with donor-derived therapeutics. It uses a platform to explore and expand multiple cell types including stem cells and natural killer cells.

In a previous article Which Genome Advanced Tech Stocks are about to change the world? we spoke about Fate Therapeutics (NASDAQ: FATE) and wrote this “Fate Therapeutics is on the top first of developing therapies for killer cells. However, in 2021 we are expecting Nkarta (NKTX) to report the results of its own trial of killer cell therapies. The stock is now $71.99 but if the trial announcements are positive, I am expecting the stock to rally up at least 50%.

Another smaller-cap stock is Gamida Cell (GMDA) an Israeli-based company that is also a clinical-stage biopharmaceutical company. The company is also developing natural killer cells and has seemed to be improving. The stock at the beginning of the month was at $6 and has now increased by 34% to $9.24”.

Only a few hours ago, Gamida Cell released the results of Phase 3 clinical study of omidubicel presented in an oral session at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blood & Marrow Transplant Research (CIBMTR), or the TCT Meetings.

The stock price closed yesterday at a price of $9.89 and is now up 82% at a price of $18.03.

 

gamida cell stocks are up 82%

About Omidubicel

Omidubicel is an advanced cell therapy under the development of a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). Please note: Omidubicel is an investigational therapy, and its safety and efficacy have not been established by the FDA or any other health authority.

The clinical data was taken from the international, randomized Phase 3 study of omidubicel in patients that are carrying high-risk hematologic malignancies undergoing a bone marrow transplant compared to a group of patients who received a standard umbilical cord blood transplant. The ages included in the Phase 3 study were 12-65 and they did not have a matched donor.  The study included 125 people and the median age was 41. Diseases included different types of leukemia, myelodysplastic syndrome and lymphoma. Patients were enrolled at more than 30 clinical centers in the United States, Europe, Asia, and Latin America.

 “The results of this global Phase 3 study of omidubicel in patients with hematologic malignancies show that omidubicel resulted in faster hematopoietic recovery, fewer bacterial and viral infections and fewer days in the hospital, all of which are meaningful results and represent potentially important advancements in care when considering the patient experience following transplant,” said Mitchell Horwitz, M.D., principal investigator and professor of medicine at the Duke Cancer Institute. “The comparator, a transplant with umbilical cord blood, has been historically shown to result in a low incidence of graft versus host disease (GvHD) in relation to other graft sources, and in this study, omidubicel demonstrated a GvHD profile similar to the comparator. Moreover, previous studies have shown that engraftment with omidubicel is durable, with some patients in the Phase 1/2 study receiving their transplant more than 10 years ago. The data presented at this meeting indicate that omidubicel has the potential to be considered a new standard of care for patients who are in need of stem cell transplantation but do not have access to a matched donor.”

Bottom Line

If omidubicel gets approval from the Food and Drug Administration (FDA) the life of patients with high-risk hematologic malignancies can be dramatically improved. This can potentially make the stock price jump again in the future. One thing is for sure, the world is on track to cure deadly diseases with the use of advanced technology.

Disclaimer – I/we have no position in any stock mentioned. I wrote this article myself, and it expresses my personal opinions. I am not receiving any compensation for it, other than FDGT Academy. I do not have or had in the past any business relationship with any company that is mentioned in the above article.

Natalia C. - Junior Analyst at FDGT Academy

Natalia C. - Junior Analyst at FDGT Academy

I am a stock analyst/investor with prior experience and knowledge to BSc Accounting and Finance. After completing my degree and exposure to the accounting firms I decided that the direction I should choose is towards the Investment world. I completed my masters in Investment Management where it gave me solid fundamentals to build my career on. I have examined a lot of different aspects of investment, from REITS, derivatives, currencies, bonds, equity and hedge funds. I never stopped learning about the market which is why I can analyze and write articles for FDGT community always personally opinionated. My passion are green energy and electric vehicles stocks as a whole. I also had my share of analyzing the work form home stocks that are coming to take over in the upcoming years.